Press Releases :: Aerami Therapeutics Holdings, Inc.

Feb 23, 2023 9:00am EST

Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress

Jan 05, 2023 9:00am EST

Aerami Therapeutics to Present at Biotech Showcase™ 2023 during the 41st Annual J.P. Morgan Healthcare Conference Week

Dec 21, 2022 8:01am EST

Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023

Dec 21, 2022 8:00am EST

Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer

Jun 16, 2022 9:00am EDT

Aerami Therapeutics Appoints Lisa Yañez as Chief Operating Officer

Nov 18, 2021 8:30am EST

Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer

Nov 11, 2021 8:30am EST

Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors

Aug 25, 2021 9:00am EDT

Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension

Jun 24, 2021 8:00am EDT

Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension

Feb 09, 2021 9:00am EST

Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China

rss_feed News RSS